These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28633892)

  • 1. Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis.
    Bissett SL; Godi A; Jit M; Beddows S
    Vaccine; 2017 Jul; 35(32):3922-3929. PubMed ID: 28633892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine.
    Godi A; Panwar K; Haque M; Cocuzza CE; Andrews N; Southern J; Turner P; Miller E; Beddows S
    Vaccine; 2019 Apr; 37(18):2455-2462. PubMed ID: 30926298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.
    Mariz FC; Gray P; Bender N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel HM; Waterboer T; Müller M; Pawlita M; Lehtinen M
    Lancet Infect Dis; 2021 Oct; 21(10):1458-1468. PubMed ID: 34081923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
    Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine.
    Godi A; Bissett SL; Miller E; Beddows S
    PLoS One; 2015; 10(10):e0140926. PubMed ID: 26495976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
    Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
    Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.
    Malagón T; Drolet M; Boily MC; Franco EL; Jit M; Brisson J; Brisson M
    Lancet Infect Dis; 2012 Oct; 12(10):781-9. PubMed ID: 22920953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.
    Ahmed AI; Bissett SL; Beddows S
    Infect Genet Evol; 2013 Aug; 18():151-9. PubMed ID: 23722024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines.
    Stanley M; Joura E; Yen GP; Kothari S; Luxembourg A; Saah A; Walia A; Perez G; Khoury H; Badgley D; Brown DR
    Vaccine; 2021 Apr; 39(16):2214-2223. PubMed ID: 33658126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity of Human Papillomavirus (HPV) Lineage and Sublineage Variant Pseudoviruses to Neutralization by Nonavalent Vaccine Antibodies.
    Godi A; Kemp TJ; Pinto LA; Beddows S
    J Infect Dis; 2019 Nov; 220(12):1940-1945. PubMed ID: 31412122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.
    Bissett SL; Draper E; Myers RE; Godi A; Beddows S
    Vaccine; 2014 Feb; 32(10):1139-46. PubMed ID: 24440205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines.
    Faust H; Toft L; Sehr P; Müller M; Bonde J; Forslund O; Østergaard L; Tolstrup M; Dillner J
    Vaccine; 2016 Mar; 34(13):1559-1565. PubMed ID: 26896686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera.
    Draper E; Bissett SL; Howell-Jones R; Edwards D; Munslow G; Soldan K; Beddows S
    Vaccine; 2011 Nov; 29(47):8585-90. PubMed ID: 21939712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of high-risk HPV and its genotypes-Implications in the choice of prophylactic HPV vaccine.
    Suresh A; Suresh P; Biswas R; Rajanbabu A; Sreedhar S; Biswas L
    J Med Virol; 2021 Aug; 93(8):5188-5192. PubMed ID: 33851736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection.
    Kemp TJ; Hildesheim A; Safaeian M; Dauner JG; Pan Y; Porras C; Schiller JT; Lowy DR; Herrero R; Pinto LA
    Vaccine; 2011 Mar; 29(11):2011-4. PubMed ID: 21241731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained Cross-reactive Antibody Responses After Human Papillomavirus Vaccinations: Up to 12 Years Follow-up in the Finnish Maternity Cohort.
    Kann H; Lehtinen M; Eriksson T; Surcel HM; Dillner J; Faust H
    J Infect Dis; 2021 Jun; 223(11):1992-2000. PubMed ID: 33009576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human Papillomavirus (HPV) Genotyping Assay Suitable for Monitoring the Impact of the 9-Valent HPV Vaccine.
    Kukimoto I; Matsumoto K; Takahashi F; Iwata T; Tanaka K; Yamaguchi-Naka M; Yamamoto K; Yahata H; Nakabayashi M; Kato H; Tsuda N; Onuki M; Yaegashi N;
    Tohoku J Exp Med; 2020 Aug; 251(4):287-294. PubMed ID: 32759554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids.
    Handisurya A; Schellenbacher C; Haitel A; Senger T; Kirnbauer R
    Br J Cancer; 2016 Feb; 114(4):409-16. PubMed ID: 26867163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-risk human papillomavirus genotypes distribution in a cohort of HIV-positive women living in Europe: epidemiological implication for vaccination against human papillomavirus.
    Konopnicki D; Manigart Y; Gilles C; Barlow P; De Marchin J; Feoli F; Delforge M; Clumeck N; De Wit S
    AIDS; 2016 Jan; 30(3):425-33. PubMed ID: 26765936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.